Skip to main content

Table 4 Factors associated with a positive MP-specific IgM at the time of admission in children hospitalized due to MP pneumonia

From: Clinical significance of Mycoplasma pneumoniae specific IgM titer in children hospitalized with Mycoplasma pneumoniae pneumonia

Variables

OR

aORa (95% CI)

P value

Age, years

0.926 (0.84–1.02)

3.64 (0.38–34.54)

0.261

Duration between symptom onset and admission, days

1.46 (1.24–1.73)

1.47 (1.24–1.75)

< 0.001

Total duration of fever during illness, days

1.16 (1.03–1.30)

1.15 (1.02–1.30)

0.019

Total hospitalization duration, days

1.09 (0.99–1.19)

1.08 (0.98–1.18)

0.107

Development of any extra-pulmonary symptoms

7.08 (1.61–31.10)

9.16 (1.96–42.81)

0.005

Hemoptysis

0.10 (0.01–0.96)

0.13 (0.01–1.45)

0.097

White blood cells, /µL

1.23 (1.07–1.40)

1.23 (1.07–1.41)

0.003

Serum lactate dehydrogenase, IU/L

1.00 (1.00-1.01)

1.00 (1.00-1.01)

0.001

Serum albumin, g/dL

1.07 (0.83–1.37)

1.08 (0.84–1.39)

0.558

Respiratory virus co-infection, yes, n (%)

1.70 (0.78–3.70)

1.36 (0.59–3.14)

0.466

Positive results on pneumobacter PCR except MP, n (%)

0.56 (0.16–1.96)

0.47 (0.11–1.98)

0.301

Respiratory virus co-infection or positive results on pneumobacter PCR except MP, n (%)

1.62 (0.77–3.44)

1.40 (0.63–3.10)

0.414

Response to stepwise treatment in MP pneumonia

 Good response

Ref

Ref

 

 Poor responseb

2.06 (0.97–4.35)

1.87 (0.84–4.18)

0.128

Severity of MP pneumonia based on the extent of pneumonic lesion on chest radiography at the time of admission

 Mild

Ref

Ref

 

 Moderate

1.75 (0.62–4.93)

2.17 (0.72–6.57)

0.171

 Severe

3.62 (0.96–13.64)

4.68 (1.12–19.55)

0.034

  1. aOR: adjusted odd ratios; IgM: immunoglobulin M; MP: Mycoplasma pneumoniae; OR: odds ratio; PCR: polymerase chain reaction; Ref: reference
  2. a*Adjusted for age, sex, macrolide resistance of MP, and duration between symptom onset and performance date of MP-specific IgM test
  3. b*Poor response includes slow response, no response and progression to stepwise treatment for MP pneumonia